Vertex's (VRTX) ViaCyte Acquisition "Adds Additional Shots on Goal" - BMO Capital Reiterates Stock at Outperform with $325 Price Target
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $325.00 price target on Vertex (NASDAQ: VRTX), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
